1. Home
  2. Labeler Index
  3. Zameer Pharmaceuticals Llc
  4. 90096-141
  5. Product Images: Trospium Chloride

Product Images Trospium Chloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Trospium Chloride NDC 90096-141 by Zameer Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - Label tros

Label - Label tros

Trozslum Chloride Tablets, USP is a drug distributed by Zameer Pharmaceuticals LLC, consisting of 60 film-coated tablets, each contains 20mg of Trospium Chloride, USP. It is important to keep this drug out of reach of children and store it within the range of 15-30°C. Dispense in tight containers as defined by USP. For further information, refer to the package insert and prescribing information.*

Fig 2 - draft labeling 1

Fig 2 - draft labeling 1

Table 4 - draft labeling 10

Table 4 - draft labeling 10

Table 4 shows the efficacy of Trospium chloride tablets in comparison to Placebo for urinary frequency, urge incontinence episodes, and void volume in Study 2. The table displays the mean change from baseline to week 12 or last observation carried forward (LOCF) for each endpoint. The treatment differences were assessed by analysis of variance for ITTLOCF data set for urinary frequency and urinary void volume, and by ranked analysis of variance for ITTLOCE data set for urge incontinence episodes. Trospium chloride tablets showed a statistically significant reduction in urinary frequency and urge incontinence episodes compared to placebo. The mean change from baseline for Trospium chloride tablets was -27(02) for urinary frequency, -161(10) for urge incontinence episodes, and 356 (28) for urinary void volume. The values in the table are reported as Mean (SE) and P-values are also provided.*

Fig 3 - draft labeling 2

Fig 3 - draft labeling 2

Fig 4 - draft labeling 3

Fig 4 - draft labeling 3

Fig 5 - draft labeling 4

Fig 5 - draft labeling 4

structure - draft labeling 6

structure - draft labeling 6

Table 1 - draft labeling 7

Table 1 - draft labeling 7

This is a table showing the adverse reactions experienced by patients taking Trospium chloride tablets 20 mg twice a day. The reactions are divided into different categories. The most common adverse reactions reported were dry mouth and constipation. Other adverse reactions reported include abdominal pain, dyspepsia, headache, fatigue, urinary retention and dry eyes. The numbers between the brackets indicate the percentage of patients who experienced each adverse reaction. The numbers outside the brackets indicate the number of patients who experienced each adverse reaction. The price of the tablets is also included (¥=590).*

table 2 - draft labeling 8

table 2 - draft labeling 8

This is a pharmacokinetic parameter estimates table for 20mg Trospium Chloride tablets in Healthy Volunteers. The table includes the mean and standard deviation values for AUCp and Tax. However, the units used for the values are not clear due to the poor quality of .*

Table 3 - draft labeling 9

Table 3 - draft labeling 9

Table 3 shows the mean change from baseline to the end of treatment in Study 1 for urinary frequency, urge incontinence episodes, and void volume. The data indicates a significant improvement for patients taking Trospium chloride tablets compared to those taking a placebo. Treatment differences were assessed by analysis of variance for ITTLOCE data set.*

Fig 1 - draft labeling

Fig 1 - draft labeling

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.